In another study of NSCLC patients treated with pembrolizumab or nivolumab, high baseline sPD-L1 associated with shorter PFS (median: 57 vs 177 days) and OS (median: 182 vs > 1000 days) [73]. Here, SPDL1 is linked to non-small cell lung carcinoma.